Skip to content

Funding for excellent research extended: LIT Scientists’ contribution is key in CRC/Transregio 221

The German Research Foundation (DFG) has extended the Collaborative Research Center (CRC) Transregio 221 “Regulation of Graft-versus-Host and Graft-versus-Leukemia Immune Responses after Allogeneic Stem Cell Transplantation” for a third funding period of four years, committing 15 million euros in support to the participating partners.

  • Date Published

    January 27, 2026

Researchers from the Leibniz Institute for Immunotherapy (LIT) play a key role in this large interdisciplinary research consortium and represent excellence in immunomedicine. A total of seven research groups at LIT are working in a research consortium with the universities of Regensburg, Erlangen-Nuremberg, and Würzburg, as well as the university hospitals there, to better understand the underlying immunological mechanisms and make the therapy even safer and more effective.

Find out more about the CRC/Transregio 221